Strategic Partnership ORCOSA is actively collaborating with leading research institutions and physicians to support FDA-authorized investigator-initiated clinical trials using the RITe Platform, presenting a clear opportunity to propose research collaborations, sponsored studies, and co-development arrangements with contract research organizations and academic medical centers.

Therapeutic Focus The company targets non-addictive CBD-based pain management with a fast-acting tablet, highlighting a potential market for partnerships with pain management clinics, formulary inclusion discussions, and healthcare providers seeking opioid alternatives.

Recent Leadership Recent hire of a COO and CFO signals a strengthening management team and funding governance, suggesting readiness for scaled operations, investor outreach, and enterprise sales efforts for manufacturing, supply chain, and regulatory services.

Phase-Ready Platform RITe Platform and compliant U.S. manufacturing indicate capability to support clinical-to-commercial rollouts, enabling conversations with contract manufacturers, supply chain partners, and distributors about scalable production and regulatory-ready formulation development.

Early Revenue & Funding Current revenue and $11M funding position ORCOSA as a venture-backed biotech with expansion potential, inviting dialogue with strategic investors, tier-one biopharma partners, and collaboration opportunities to accelerate product development and market entry.